What is Protein A-VC-MMAE ADC?

Protein A-VC-MMAE ADC is an antibody-drug conjugate composed of Protein A conjugated via a VC linker to the cytotoxic drug MMAE.

How does the VC linker function in this ADC?

The VC linker is a cleavable linker that releases MMAE inside target cells after internalization, enhancing the specificity and efficacy of the ADC.

What types of cancers can this ADC target?

It targets cancers through immunorecognition and receptor-mediated endocytosis, but specific cancer types depend on the primary antibody used.

Is this ADC suitable for in vivo studies?

Yes, but optimal dosing and potential side effects should be carefully evaluated in preliminary studies.

What are the potential side effects of using this ADC in vivo?

Potential side effects may include cytotoxicity to non-target cells if the ADC is not sufficiently specific.

What is the importance of tubulin binding in the mechanism of MMAE?

Binding to tubulins disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in targeted cancer cells.

Home
Products
Anti-Ab ADCs
IgG Fc
Protein A-VC-MMAE ADC

Protein A-VC-MMAE ADC (CAT#: ADC-AA-052)

This ADC product is comprised of a Protein A conjugated via a VC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Protein A

Name
VC (valine-citrulline)

Description
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.

Name
MMAE (Monomethyl auristatin E)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-052. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Highly effective ADC! Protein A-VC-MMAE showed excellent cancer cell targeting and induced cell death efficiently. Very satisfied.

Excellent

Highly recommend.

Excellent performance in our lab. The VC linker and MMAE combination worked perfectly for receptor-mediated endocytosis.

Excellent

Impressive ADC

The tubulin binding and microtubule disruption led to significant cell death in our cancer studies. Outstanding quality.

Excellent

Protein A-VC-MMAE ADC provided precise targeting with minimal background effects. Economical and effective for our research.

Excellent

Will use again

Top-notch product from Creative Biolabs. The glycosylation and Fc receptor binding were ideal for our ADCC assays.

Excellent

Great service

Very efficient ADC for cancer research. The MMAE induced cell death effectively, and the product was delivered promptly.

Q: 1: What is Protein A-VC-MMAE ADC?
A: Protein A-VC-MMAE ADC is an antibody-drug conjugate composed of Protein A conjugated via a VC linker to the cytotoxic drug MMAE.
Q: 2: How does the VC linker function in this ADC?
A: The VC linker is a cleavable linker that releases MMAE inside target cells after internalization, enhancing the specificity and efficacy of the ADC.
Q: 3: What types of cancers can this ADC target?
A: It targets cancers through immunorecognition and receptor-mediated endocytosis, but specific cancer types depend on the primary antibody used.
Q: 4: Is this ADC suitable for in vivo studies?
A: Yes, but optimal dosing and potential side effects should be carefully evaluated in preliminary studies.
Q: 5: What are the potential side effects of using this ADC in vivo?
A: Potential side effects may include cytotoxicity to non-target cells if the ADC is not sufficiently specific.
Q: 6: What is the importance of tubulin binding in the mechanism of MMAE?
A: Binding to tubulins disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in targeted cancer cells.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-051	Protein G-Duocarmycin ADC		Duocarmycins
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-W-476	Anti-SLC44A4 (AGS-5)-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-W-462	Anti-GPNMB-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-056	Anti-MIgG (clone 187.1)-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-W-529	Anti-F3 (TF-011)-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-048	Protein G-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-W-494	Anti-SLC39A6-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-029	anti-MIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-W-499	Anti-SLC34A2 (Lifastuzumab)-VC-MMAE ADC	mc-VC-PABC	MMAE (Monomethyl auristatin E)
ADC-W-465	Anti-TNFRSF8 (Brentuximab)-VC-PAB-MMAE ADC	VC-PAB (valine-citrulline with PAB)	MMAE (Monomethyl auristatin E)
ADC-W-565	Anti-EDNRB-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.